Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

Similar articles for PubMed (Select 23580234)

1.

Stereotactic radiosurgery and stereotactic body radiation therapy cost-effectiveness results.

Bijlani A, Aguzzi G, Schaal DW, Romanelli P.

Front Oncol. 2013 Apr 8;3:77. doi: 10.3389/fonc.2013.00077. eCollection 2013.

2.

Medical and health economic assessment of radiosurgery for the treatment of brain metastasis.

Müller-Riemenschneider F, Schwarzbach C, Bockelbrink A, Ernst I, Vauth C, Willich SN, von der Schulenburg JM.

GMS Health Technol Assess. 2009 Mar 9;5:Doc03. doi: 10.3205/hta000065.

3.

The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy.

Davis JN, Medbery C 3rd, Sharma S, Danish A, Mahadevan A.

Radiat Oncol. 2013 Nov 25;8:275. doi: 10.1186/1748-717X-8-275.

4.

Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.

Shah A, Hahn SM, Stetson RL, Friedberg JS, Pechet TT, Sher DJ.

Cancer. 2013 Sep 1;119(17):3123-32. doi: 10.1002/cncr.28131. Epub 2013 May 29.

5.

Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.

Amin NP, Sher DJ, Konski AA.

Appl Health Econ Health Policy. 2014 Aug;12(4):391-408. doi: 10.1007/s40258-014-0106-9. Review.

PMID:
25022451
6.

Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer.

Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD.

Am J Manag Care. 2012 May 1;18(5):e186-93.

7.

Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.

Kim H, Rajagopalan MS, Beriwal S, Huq MS, Smith KJ.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):556-63. doi: 10.1016/j.ijrobp.2014.10.055. Epub 2015 Jan 30.

PMID:
25680599
8.

Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.

Murphy JD, Chang DT, Abelson J, Daly ME, Yeung HN, Nelson LM, Koong AC.

Cancer. 2012 Feb 15;118(4):1119-29. doi: 10.1002/cncr.26365. Epub 2011 Jul 19.

9.

Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.

Parthan A, Pruttivarasin N, Davies D, Taylor DC, Pawar V, Bijlani A, Lich KH, Chen RC.

Front Oncol. 2012 Aug 20;2:81. doi: 10.3389/fonc.2012.00081. eCollection 2012.

10.
11.

Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer.

Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD.

J Oncol Pract. 2012 May;8(3 Suppl):e31s-7s. doi: 10.1200/JOP.2012.000548.

12.

Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.

Sher DJ, Wee JO, Punglia RS.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e767-74. doi: 10.1016/j.ijrobp.2010.10.074. Epub 2011 Feb 6.

PMID:
21300476
13.

Economic impact of stereotactic radiosurgery for malignant intracranial brain tumors.

Lal LS, Franzini L, Panchal J, Chang E, Meyers CA, Swint JM.

Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):195-204. doi: 10.1586/erp.11.10. Review.

PMID:
21476821
14.
15.

Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer.

Mitera G, Swaminath A, Rudoler D, Seereeram C, Giuliani M, Leighl N, Gutierrez E, Dobrow MJ, Coyte PC, Yung T, Bezjak A, Hope AJ.

J Oncol Pract. 2014 May;10(3):e130-6. doi: 10.1200/JOP.2013.001206. Epub 2014 Mar 18.

16.

Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases.

Lal LS, Byfield SD, Chang EL, Franzini L, Miller LA, Arbuckle R, Reasonda L, Feng C, Adamus A, Swint JM.

Am J Clin Oncol. 2012 Feb;35(1):45-50. doi: 10.1097/COC.0b013e3182005a8f.

PMID:
21293245
17.

Best of the Radiosurgery Society® Scientific Meeting 2014: stereotactic radiosurgery/stereotactic body radiotherapy treatment of extracranial and intracranial lesions.

Mahadevan A, Bucholz R, Gaya AM, Kresl JJ, Mantz C, Minnich DJ, Muacevic A, Medbery C 3rd, Yang J, Caglar HB, Davis JN.

Future Oncol. 2014 Dec;10(15):2307-10. doi: 10.2217/fon.14.168.

18.

Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.

Sher DJ, Parikh RB, Mays-Jackson S, Punglia RS.

Am J Clin Oncol. 2014 Jun;37(3):215-21. doi: 10.1097/COC.0b013e31827a7d2a.

PMID:
23275277
19.

A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.

Puri V, Crabtree TD, Kymes S, Gregory M, Bell J, Bradley JD, Robinson C, Patterson GA, Kreisel D, Krupnick AS, Meyers BF.

J Thorac Cardiovasc Surg. 2012 Feb;143(2):428-36. doi: 10.1016/j.jtcvs.2011.10.078. Epub 2011 Dec 9.

PMID:
22169443
20.

Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.

Louie AV, Rodrigues G, Hannouf M, Zaric GS, Palma DA, Cao JQ, Yaremko BP, Malthaner R, Mocanu JD.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):964-73. doi: 10.1016/j.ijrobp.2010.06.040. Epub 2010 Oct 6.

PMID:
20932688
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk